Isomyosamine

Phase 2Small molecule

TTNF Pharmaceuticals, Inc.

Isomyosamine is one of 36 small molecule programs targeting Bone Fracture. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone FractureActive, not recruiting

Bone FracturePhase 2

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Bone Fracture

#DrugCompanyPhaseTrials

Fareston

Kyowa Kirin Co., Ltd.

Epidiolex

Voltaren

Bayer Aspirin

Zometa

Keterol

PPamukkale University

Approved

1 7

Toradol

JJavelin Pharmaceuticals

Approved

1 8

Advil

KKenvue Brands

Approved

1 9

Tylenol

KKenvue Brands

Approved

1 10

Ultram

WWim Janssens

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone Fracture1 trial

Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures

Not yet recruiting·TTNF Pharmaceuticals, Inc.·Phase 2·NCT06942182·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Isomyosamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isomyosamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isomyosamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TNF Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTNF Pharmaceuticals, Inc.

Isomyosamine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone Fracture1 trial

References

Drug Info

Quick Facts

Related News